Spark Biomedical, the parent company of OhmBody, a women’s wellness division focused on wearable neurostimulation technology, has published the first peer-reviewed human trial evaluating transcutaneous auricular neurostimulation (tAN) for menstrual health. The study, now available in Frontiers in Medicine, demonstrates meaningful reductions in heavy menstrual bleeding (HMB) and related symptoms.

The pilot study included 16 participants, including women with von Willebrand Disease (VWD) and those with HMB of unknown cause. Participants using OhmBody’s wearable tAN device daily during menstruation experienced on average a reduction in menstrual blood loss by more than 50% and shorter periods by nearly 20%. Improvements were also reported in cramping, fatigue, and overall quality of life.

tAN engages the body’s natural nervous system via the vagus and trigeminal nerves, providing a non-invasive, drug-free approach to managing HMB. These findings suggest a new option for women whose heavy menstrual bleeding is inadequately addressed by current treatments.

“This peer-reviewed study provides the first clinical evidence that wearable neurostimulation can meaningfully improve menstrual health,” said Daniel Powell, CEO and Co-Founder of Spark Biomedical. “For millions of women, this offers a non-invasive, drug-free way to manage heavy bleeding and improve daily life.”

“Heavy menstrual bleeding is widespread and often under-treated,” said Navid Khodaparast, PhD, Chief Science Officer and Co-Founder at Spark Biomedical. “Our findings show that neuromodulation can provide real relief and support overall well-being.”

Spark Biomedical and OhmBody are committed to advancing women’s health research and continue to explore innovative ways to support menstrual health. The study is available online in Frontiers in Medicine.

‍